Literature DB >> 12536201

RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines.

Daniel P Cioca1, Yuji Aoki, Kendo Kiyosawa.   

Abstract

BACKGROUND: RNA interference (RNAi) is a cellular pathway of gene silencing in a sequence-specific manner at the messenger RNA level. The basic mechanism behind RNAi is the breaking of a double-stranded RNA (dsRNA) matching a specific gene sequence into short pieces called short interfering RNA, which trigger the degradation of mRNA that matches its sequence. In this study, we explored the effects of RNAi in reducing the target gene expression in human myeloid leukemia cell lines.
METHODS: Four myeloid leukemia cell lines (HL-60, U937, THP-1, and K562) were transfected with dsRNA duplexes corresponding to the endogenous c-raf and bcl-2 genes and the gene expression inhibition was assessed. The effect of RNAi on cell differentiation was studied; the apoptosis induction and the sensitization of the leukemia cell lines to etoposide and daunorubicin were quantified by flowcytometric methods.
RESULTS: Transfection of the myeloid leukemia cell lines with dsRNA corresponding to c-raf and bcl-2 genes decreased the expression of Raf-1 and Bcl-2 proteins. RNAi for c-raf gene blocked the appearance of the monocytic differentiation induced by treatment with TPA. Combined RNAi for c-raf and bcl-2 induced apoptosis in HL-60, U937, and THP-1 cells and increased chemosensitivity to etoposide and daunorubicin.
CONCLUSIONS: RNAi is a functional pathway in human myeloid leukemia cell lines and combined RNAi of c-raf and bcl-2 genes may represent a novel approach to leukemia, providing a means to overcome the resistance to chemotherapeutic agents and ultimately to augment the efficacy of chemotherapy in myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12536201     DOI: 10.1038/sj.cgt.7700544

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  27 in total

Review 1.  RNA interference: ready to silence cancer?

Authors:  Simone Mocellin; Rodolfo Costa; Donato Nitti
Journal:  J Mol Med (Berl)       Date:  2005-11-09       Impact factor: 4.599

2.  MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas.

Authors:  Kepal N Patel; Ellie Maghami; Volkert B Wreesmann; Ashok R Shaha; Jatin P Shah; Ronald Ghossein; Bhuvanesh Singh
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

3.  The effect of Bcl-2 siRNA combined with miR-15a oligonucleotides on the growth of Raji cells.

Authors:  Xiaomao Hu; Wenyu Li; Gexiu Liu; Hong Wu; Yangjun Gao; Shengting Chen; Dongmei He; Yuan Zhang
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

4.  Downregulation of BCL11A by siRNA induces apoptosis in B lymphoma cell lines.

Authors:  Yangjun Gao; Hong Wu; Dongmei He; Xiaomao Hu; Yangqiu Li
Journal:  Biomed Rep       Date:  2012-09-05

5.  Silencing of HMGA1 expression by RNA interference suppresses growth of osteogenic sarcoma.

Authors:  Shaohui Yuan; Qi Pan; Chunjiang Fu; Zhenggang Bi
Journal:  Mol Cell Biochem       Date:  2011-05-15       Impact factor: 3.396

6.  RNA interference-mediated gene silencing of vascular endothelial growth factor in colon cancer cells.

Authors:  Tie-Jun Li; Jian-Ning Song; Kai Kang; Shu-Sheng Tong; Zan-Lan Hu; Tong-Chuan He; Bing-Qiang Zhang; Cai-Quan Zhang
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

7.  Genetic variants contributing to daunorubicin-induced cytotoxicity.

Authors:  R Stephanie Huang; Shiwei Duan; Emily O Kistner; Wasim K Bleibel; Shannon M Delaney; Donna L Fackenthal; Soma Das; M Eileen Dolan
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells.

Authors:  Wenjia Guo; Hailong Tian; Xiaogang Dong; Jinping Bai; Xinling Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  Fenoterol, a beta(2)-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through beta-arrestin-2 in THP-1 cell line.

Authors:  Wei Wang; Ming Xu; You-yi Zhang; Bei He
Journal:  Acta Pharmacol Sin       Date:  2009-11       Impact factor: 6.150

10.  Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts.

Authors:  Q Leng; P Scaria; P Lu; M C Woodle; A J Mixson
Journal:  Cancer Gene Ther       Date:  2008-05-16       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.